A Study to Evaluate the Efficacy and Safety of IBI363 Monotherapy Compared to Pembrolizumab in Patients With Unresectable Locally Advanced or Metastatic Mucosal or Acral Melanoma Who Had Not Previously Received Systemic Therapy
Clinical trial NCT06797297 · RECRUITING
Trial details
- NCT number
- NCT06797297
- Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
- Status
- RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2025-02-24
- Primary completion
- 2026-03-31
- Enrollment
- 180
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.